Clinicopathological Characteristics and Prognosis of Non-Small Cell Lung Cancer Patients Associated with a Family History of Lung Cancer by Haraguchi, Shuji et al.
Int. J. Med. Sci. 2012, 9 
 
 
http://www.medsci.org 
68 
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   M Me ed di ic ca al l   S Sc ci ie en nc ce es s   
2012; 9(1):68-73 
Research Paper 
Clinicopathological Characteristics and Prognosis of Non-Small Cell Lung 
Cancer Patients Associated with a Family History of Lung Cancer 
Shuji Haraguchi1, 2, Kiyoshi Koizumi1, 2, Iwao Mikami1, 2, Okamoto Junichi1, 2, Yoshihito Iijima1, 2, Takayuki 
Ibi1, 2, Kazuo Shimizu2  
1.  Department of Surgery, Division of Thoracic Surgery, Nippon Medical School, Tokyo, Japan. 
2.  Department of Biological Regulation and Regenerative Surgery, Graduate School of Medicine, Nippon Medical School, 
Tokyo, Japan.  
 Corresponding author: Shuji Haraguchi, MD, Department of Surgery, Division of Thoracic Surgery, Nippon Medical 
School,  1-1-5  Sendagi,  Bunkyo-ku,  Tokyo,  113-8603,  Japan.  Tel.,  03-3822-2131  (business),  048-261-9733  (home),  Fax, 
03-5685-0985 (business), E-mail, shuji@nms.ac.jp 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.10.04; Accepted: 2011.11.20; Published: 2011.11.30 
Abstract 
Introduction: Clinicopathological characteristics and prognosis of non-small cell lung cancer 
(NSCLC) patients with a family history of lung cancer (FHLC) have not been well established.  
Methods: Clinical records of patients with NSCLC treated at our institute from 1982 to 
2010 were reviewed with special reference to family history of lung cancer and clinico-
pathological factors including patient’s outcome. Univariate analyses of the factors between 
the groups of FHLC and non-FHLC were performed using unpaired two-tailed t tests or the 
chi-square test. The Cox proportional hazards model was used to evaluate the hazard ratio of 
death.  
Results: Of the 1013 NSCLC patients, 124 (12.2%) had a FHLC of whom 119 (96%) were the 
first-degree relatives. The frequency of early stages of lung cancer was high in both groups of 
FHLC and non-FHLC patients. Patients with FHLC had a significantly higher frequency of early 
pathological stages and a prepomderance of adenocarcinoma, and a hazard ratio of death of 
0.870 (95% confidence interval: 0.599-1.263, p value: 0.465) compared with the non-FHLC 
patients.  
Conclusions: NSCLC patients with FHLC could be characterized by early pathological stages 
and preponderance of adenocarcinoma, however they were not at a decreased hazard ratio of 
death. These findings emphasize the importance of early detection of lung cancer and em-
ployment of less invasive therapeutic interventions. 
Key words: non-small cell lung cancer, family history of lung cancer, clinicopathological charac-
teristics, prognosis, hazard ratio of death. 
Introduction 
A familial aggregation of lung cancer is reported 
in various populations even in patients without a he-
reditary cancer syndrome [1-7]. However, the clinical 
characteristics and prognosis of lung cancer patients 
associated  with  a  family  history  of  lung  cancer 
(FHLC) have not been well established [6, 7]. Several 
studies  have  examined  the  relationship  between 
FHLC and lung cancer risk and have reported a fa-
vorable correlation [1, 2, 6, 7, 8-13], whereas others 
have  not  observed  such  an  association  [14,  15].  To 
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provide further insights into this issue, we conducted 
a comprehensive review of the clinical records of all 
patients  with  non-small  cell  lung  cancer  (NSCLC) 
treated  at  our  institute  during  a  long  period  of  28 
years.  Subsequently,  we  assessed  the  clinicopatho-
logical characteristics and prognosis of patients with 
FHLC and compared the results with lung cancer pa-
tients without FHLC (non-FHLC). 
Methods 
Subjects 
From  February  1982  to  March  2010,  1,502  pa-
tients underwent a resection for NSCLC at the Divi-
sion of Thoracic Surgery, Department of Surgery of 
Nippon Medical School. Of these, 387 patients were 
excluded from the study due to the lack of a detailed 
family history. Therefore, 1,013 patients including 723 
men  and  290  women  were  analyzed  in  the  present 
study. Of the 1,013 patients, 125 (12.2%) including 87 
men and 38 women were patients with FHLC (FHLC 
group).The mean age of the patients with FHLC and 
non-FHLC  groups  were  66  years  old  (range,  38-84 
years old) and 65 years old (range, 20-95 years old), 
respectively.  The  FHLC  group  had  732  first-degree 
relatives, and 120 patients had 130 first-degree rela-
tives  with  lung  cancer  including  89  men  and  41 
women  (65  siblings,  39  fathers,  25  mothers,  and  1 
child)  and  6  patients  had  6  second-degree  relatives 
with lung cancer  including 5 men and 1 women (3 
uncles,  1  aunt,  1  grandfather,  and  1  nephew).  The 
lung cancers of all the patients were staged clinically 
and pathologically according to the seventh edition of 
TNM staging system for lung cancer [16]. In this se-
ries, parents, siblings and offspring are considered as 
first-degree relatives, grandparents, uncles, aunts, and 
nephews are second-degree relatives, and cousins as 
third-degree relatives [2, 3, 6, and 7]. 
The  postoperative  pulmonary  functions  were 
predicted according to a simplified system, which we 
developed using plain chest roentgenograms  of pa-
tients  with  primary  lung  cancer  [16,  17].  The 
ppoFEV1.0  is  (42-R)/(42-T) × preoperative  FEV1.0, 
where R is the number of subsegments scheduled for 
lung resection and T is number of tumor-related sub-
segments. T is determined as follows: (a) if a tumor is 
located in the periphery of the lung, the T factor is 
equal to 1 in the case of a tumor 3 cm or less in its 
largest dimension and equal to 2 in the case of a tumor 
more than 3 cm in its largest dimension; and (b) if a 
tumor obstructs large airways, the T factor is equal to 
the number of subsegments involved in atelectasis or 
postobstructive pneumonia [17, 18]. 
Statistics 
Statistical analyses were performed between the 
FHLC and non-FHLC groups, using IBM SPSS Statis-
tics  version  19  (IBM  SPSS,  New  York,  USA).  Only 
first-degree  relatives  were  used  in  the  analyses  be-
cause  we  suspected  incomplete  information  of  se-
cond-degree  relatives  from  disproportion  between 
numbers  of  first-  and  second-degree  relatives.  Uni-
variate analyses between the groups were performed 
by  means  of  unpaired  two-tailed  t  tests  or  the 
chi-square test, using age, sex, smokers versus never 
smokers, symptoms at the time of discovery of lung 
cancer (asymptomatic versus symptomatic), with and 
without  diagnosis  before  surgery,  operative  proce-
dures  (pneumonectomy  versus  others),  pathological 
stage (stage I or II versus stage III or IV), histological 
type of lung cancer (adenocarcinoma versus others).  
For statistical analyses of prognostic factors for 
the overall survival of lung cancer patients, we parti-
tioned the patients by age (above  versus below the 
median of 65 years), sex, smokers or never smokers, 
the FHLC group versus the non-FHLC group, symp-
toms at diagnosis (asymptomatic versus symptomat-
ic), with and without diagnosis of lung cancer before 
surgery,  operative  procedures  (pneumonectomy 
versus others), pathological stage (stage I or II versus 
stage III or IV), and histological type of lung cancer 
(adenocarcinoma  versus  others).  For  the  univariate 
analyses, the overall survival for subgroups described 
above was statistically analyzed using Kaplan-Meier 
estimated survival curves, and the significance of the 
difference  was  analyzed  by  the  log-rank  test.  After 
adjusting  for  those  prognostic  factors,  the  Cox  pro-
portional hazards model was used to evaluate the risk 
of  death  of  the  FHLC  group  compared  with  the 
non-FHLC  group.  A  p<0.05  was  considered  signifi-
cant. 
Results 
Site  of  malignancy  in  the  first-  and  se-
cond-degree relatives are shown in Table 1. Lung was 
the  secondly  frequent  site  (17.9%).  Of  125  patients 
with FHLC, 85 patients (68%) had adenocarcinoma, 32 
(25.6%)  had  squamous  cell  carcinoma,  5  (4%)  had 
large cell carcinoma, and 3 (2.5%) had others. Of 125 
patients with FHLC, 115 patients (92%) had 1 relative 
with lung cancer, 9 (7.2%) had 2 relatives with lung 
cancer, and 1 (0.8%) had 3 relatives with lung cancer. 
Of  732  first-degree  relatives,  10  patients  had  other 
smoking-related cancers (laryngeal, esophageal, pan-
creas,  bladder  carcinoma  each  in  2,  maxillary  and 
kidney carcinoma each in 1). 
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Table 1. Site of cancer in the family of lung cancer patients. 
Location  Number (%) 
1 Stomach  261 (34.3) 
2 Lung  136 (17.9) 
3 Colon (including rectum)  80 (10.5) 
4 Liver   52 (6.8) 
5 Uterus   41 (5.4) 
6 Mammary gland   28 (3.7) 
7 Esophagus   26 (3.4) 
8 Pancreas   21 (2.8) 
9 Larynx   15 (2.0) 
10 Prostate   14 (1.8) 
11 Bladder   11 (1.4) 
12 Central nerve system   11 (1.4) 
13 Blood   9 (1.2) 
14 Skin    8 (1.1) 
15 Lymph node   8 (1.1) 
16 Kidney   7 (0.9) 
17 Gall bladder and bile duct   6 (0.8) 
18 Tongue   5 (0.7) 
19 Bone   5 (0.7) 
20 Ovary   4 (0.5) 
21 Maxillary antrum   4 (0.5) 
22 Pharynx   2 (0.3) 
23 Thyroid   2 (0.3) 
24 Oral   1 (0.1) 
25 Gingival   1 (0.1) 
26 Urinary tract   1 (0.1) 
27 Peripheral nerve   1 (0.1) 
 
 
The  clinicopathological  characteristics  of  the 
FHLC and non-FHLC groups are shown in Table 2. 
The FHLC group had significantly early pathological 
stages of lung cancer as compared with the non-FHLC 
group.  The  FHLC  group  had  a  significantly  more 
frequency of adenocarcinoma as compared with the 
non-FHLC group. The clinicopathological character-
istics of the FHLC and non-FHLC groups in adeno-
carcinoma patients alone are shown in Table 3. There 
was  no  significant  difference  in  frequency  of  early 
pathological stages of lung cancer between the FHLC 
and non-FHLC groups. 
Univariate analyses of the prognostic factors for 
the overall survival of lung cancer patients revealed 
that sex, symptoms at diagnosis, pathological stage, 
operative  procedure,  never  smokers,  and  histology 
were the significant risk factors (Table 4). After ad-
justing these risk factors, the FHLC group had a haz-
ard ratio of death of 0.820 (95% confidence interval: 
0.558-1.204,  p  value:  0.311)  as  compared  with  the 
non-FHLC group (Table 5). 
The  5-year  overall  survival  was  65%  for  the 
FHLC  group  and  58%  for  the  non-FHLC  group 
(p=0.1399). The 5-year overall survival for lung cancer 
patients  with  p-stage  I  /II  was  71.2%  in  the  FHLC 
group and 70.7% in the non-FHLC group (p=0.8834). 
The 5-year overall survival for lung cancer patients 
with p-stage I /II and adjuvant therapy was 69 .2% in 
the FHLC group and 68.1% in the non-FHLC group 
(p=0.981). The 5-year overall survival for lung cancer 
patients with p-stage III/ IV was 36.2% in the FHLC 
group and 29.4% in the non-FHLC group (p=0.4986). 
The 5-year overall survival for lung cancer patients 
with p-stage III/ IV and adjuvant therapy was 35.4% 
in  the  FHLC  group  and  49.5%  in  non-FHLC  group 
(p=0.195).  
 
 
 
 
Table 2. Clinicopathological characteristics of patients 
with family history of lung cancer (FHLC) versus without 
family history of lung cancer (non-FHLC). 
  FHLC (%)  non- 
FHLC 
(%) 
P value  
Number of patients  120  889  NAs 
Age  66±9  65±10  0.446 
 <50 years  5 (4)  60 (7)  0.288 
Sex       
Male  84 (71)  637 (72)   
Female  35 (29)  252 (28)  0.809 
Smokers  90 (76)  666 (75)   
Never smokers  29 (24)  223 (25)  0.866 
ppoFEV1.0 (L)  1.8±0.5  1.7±0.5  0.052 
Asymptomatic  76 (64)  598 (67)   
Symptomatic  43 (36)  291 (33)  0.459 
Diagnosis before surgery  102 (86)  774 (87)  0.682 
Operative procedures       
Pneumonectomy  8 (7)  89 (10)   
Others  111 (93)  800 (90)  0.253 
Adjuvant therapy  56 (47)  410 (46)  0.847 
Pathological stage of lung can-
cer 
     
 I, II  92 (77)  605 (68)   
 III, IV  27 (23)  284 (32)  0.040* 
Histological type of lung cancer 
excluding MPLC 
     
Adenocarcinoma  79 (66)  490 (55)   
Others  40 (32)  399 (45)  0.020*  
NA, not applicable; MPLC, multiple primary lung cancer; *, statis-
tically significant. 
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Table 3. Clinicopathological characteristics of adenocar-
cinoma patients with family history of lung cancer (FHLC) 
versus without family history of lung cancer (non-FHLC). 
  FHLC (%)  non- FHLC 
(%) 
P value  
Number of patients  79  490  NAs 
Age  65 ± 9  65 ± 10  0.366 
 <50  years  4 (5)  34 (7)  0.535 
Sex       
Male  50 (63)  294 (60)   
Female  29 (37)  196 (40)  0.579 
Smokers  54 (68)  303(62)   
Never smokers  25 (32)  187 (38)  0.266 
ppoFEV1.0 (L)  1.8±0.5  1.8±0.6  0.912 
Asymptomatic  60 (76)  372 (76)   
Symptomatic  19 (24)  118 (24)  0.995 
Diagnosis before surgery  67 (85)  415 (85)  0.979 
Operative procedures       
Pneumonectomy  4 (5)  23 (5)   
Others  75 (95)  467 (95)  0.886 
Adjuvant therapy  39 (49)  227 (46)  0.615 
Pathological stage of lung 
cancer 
   
 
 
 
 I, II  60 (76)  352 (72)   
 III, IV  19 (24)  138 (28)  0.448 
NA, not applicable; MPLC, multiple primary lung cancer. 
Table 4. Univariate analyses of the prognostic factors for 
the overall survival of lung cancer patients. 
Groups     Overall survival rates (%)  P value 
(Log-ra
nk)  Years 
     1  2  3  4  5   
Age <65 years  (n=459)   84  74  67  63  61    
Age ≧65 years  (n=549)   85  75  67  62  57   0.410 
Sex Male  (n=721)   82  72  63  57  53   
Sex Female  (n=281)   91  82  77  75  73   0.000* 
Never smokers  (n=252)   93  82  75  72  70   
Smokers  (n=756)   81  72  65  59  55  0.000* 
Non-FHLC  (n=889)   84  74  67  61  58   
FHLC  (n=119)   88  81  71  69  66  0.098 
Asymptomatic  (n=674)   91  84  78  72  69   
Symptomatic  (n=334)   70  56  46  42  39  0.000* 
Preoperative LC 
diagnosis 
(n=876)   84  74  66  61  58   
Postoperative LC 
diagnosis 
(n=132)   86  79  73  71  64  0.229 
Pneumonectomy  (n=97)   52  44  38  34  31   
Others  (n=911)   88  78  70  65  62  0.000* 
Pathological stage 
I, II 
(n=697)   92  86  80  75  71   
III, IV  (n=311)   65  48  37  31  30  0.000* 
Adenocarcinoma  (n=569)   89  81  74  68  64   
Others  (n=439)   78  66  59  55  52  0.000* 
FHLC, family history of lung cancer; LC, lung cancer; *, statistically 
significant. 
Table 5. Multivariate Cox proportional hazards regression 
analysis. 
Factors 
 
Hazard ratio 
of death 
 
95%CI 
 
p value  
 
Pathological stage 
(III-IV vs. I-II) 
3.432  2.723-4.325  0.000* 
Symptoms 
(Present vs. absent) 
2.090 
 
1.657-2.636 
 
0.000* 
 
Sex 
(Female vs. male) 
0.666 
 
0.478-0.927 
 
0.016* 
 
Procedures 
(Pneumonectomy vs. 
others) 
1.237 
 
0.907-1.688 
 
0.179 
 
Pathology 
(Adenocarcinoma vs. 
others) 
0.883 
 
0.697-1.120 
 
0.306 
 
FHLC 
(Present vs. absent) 
0.820 
 
0.588-1.204 
 
0.311 
 
Smoking history 
(Smokers vs. never 
smokers) 
 
1.118 
 
 
0.794-1.574 
 
 
0.522 
 
*, Statistically significant. 
 
Discussion 
Clinicopathological  characteristics  and  progno-
sis of NSCLC patients with FHLC have not been well 
established in the literature [6, 7]. The present study 
showed that 78% of the FHLC group and 68% of the 
non-FHLC  group  were  diagnosed  at  pathological 
stage I and II as compared with 18% and 15% respec-
tively in the series reported by of Ganti et al [6] and 
38% and 42% respectively in the series reported by of 
Lin et al [7]. The high frequency of early stages in the 
FHLC and non-FHLC groups may be attributable to 
the universal healthcare practice in Japan. For exam-
ple, patients aged 40 years or over can have the an-
nual chest X-ray program in Tokyo. Of 80 asympto-
matic  patients,  73  patients  were  from  the  screening 
programs. 
In  addition,  the  lung  cancers  in  FHLC  group 
were  detected  significantly  at  early  stages  as  com-
pared with the non-FHLC group. It is suggested that 
the knowledge of FHLC allows the patient to recog-
nize their predisposition to lung cancer and thus reg-
ularly attempt hospital visit for check-up. 
The  present  series  had  a  high  percentage  of 
never-smoker (24% of the FHLC group and 32% of 
adenocarcinoma  patients).  The  percentage  of  never 
smoker in the Eastern countries seems to be higher 
than that in the Western countries. In German, 4.1% 
and  5.3%  of  the  patients  aged  below  45  years  and 
between  55-69  years  in  the  FHLC  group  were  nev-
er-smoker [13]. In the United States, 5% of the FHLC 
group was never-smoker compared to 36% in China 
[6]. Furthermore, 33% of the FHLC group was nev-
er-smoker in the other series in Japan [12]. Int. J. Med. Sci. 2012, 9 
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Squamous cell carcinoma has been reported to 
be mostly associated with familial clustering of can-
cer, paticularly among women, persons younger than 
57 years, and individuals who smoked for fewer than 
20  years  [4]. Recently,  patients  in  the  FHLC  group, 
compared to those in the non-FHLC group were di-
agnosed at earlier ages and presented more cases of 
adenocarcinomas  in  China  [7].  In  our  series  a  pre-
ponderance  of  adenocarcinoma  were  observed,  but 
patients  in  the  FHLC  group  were  not  diagnosed  at 
earlier ages, even in adenocarcinoma patients. There-
fore, further study is necessary to clarify whether the 
difference  in  epidemiological  findings  is  dis-
trict-related or is due to the race. 
The multivariate analysis of the prognostic fac-
tors showed that pathological stages, symptoms at the 
time of discovery of lung cancer, and gender were risk 
factors  in  the  present  series.  Male  patients  signifi-
cantly died of lung cancer, other disease, and opera-
tive  cause  than  female  patients.  Male  patients  had 
significantly more advanced pathological stages than 
female patients. In addition, male patients had signif-
icantly  higher  operative  mortality  due  to  severe 
comorbidity (data not shown). 
An adjusted hazard ratio of death of 1.65 in the 
FHLC  group  compared  with  the  non-FHLC  group 
was found in the series reported by Ganti et al in the 
United States [6]. This risk was especially increased in 
those with an affected first-degree relative. This series 
had high frequency of small cell lung cancer. On the 
contrary, a significantly better prognosis was found in 
the  FHLC  group  than  the  non-FHLC  group  in  the 
series  reported  from  China  [7].  They  also  reported 
poorer response rate to chemotherapy in the FHLC 
group with advanced stages. However, in our study, 
there  was  no  significant  difference  in  an  adjusted 
hazard  ratio  of  death  between  the  FHLC  and 
non-FHLC groups. In support of this finding, a recent 
study on a large cohort of women with lung cancer in 
China also showed that lung cancer risk was not in-
creased among women with a family history of lung 
cancer  [15].  We  found  that  adjuvant  therapy  in  the 
early and advanced stages does not affect the survival 
in  the  FHLC  and  non-FHLC  groups.  Further,  early 
detection of lung cancer in the FHLC group contrib-
uted to an improved survival, but didn’t reach a sig-
nificant level 
Conclusions 
NSCLC  patients  with  FHLC  demonstrate  an 
early pathological stage and a preponderance of ad-
enocarcinoma, but are not at a decreased hazard ratio 
of  death  as  compared  with  those  without  FHLC. 
These  findings  emphasize  the  importance  of  early 
detection of lung cancer and employment of less in-
vasive therapeutic intervention. 
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